CHIH-HUNG HSUKUN-HUEI YEHANN-LII CHENG2020-04-282020-04-2819970250-7005https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030937624&partnerID=40&md5=7746973eff1f67a7094b9aa3ae3245d1https://scholars.lib.ntu.edu.tw/handle/123456789/487388Thymic carcinoma is known for its poor clinical outcome and unsatisfactory response to conventional chemotherapy. A 53-year-old woman was diagnosed as having metastatic thymic carcinoma in 1989. She received systemic chemotherapy containing cisplatin, doxorubicin, and cyclophosphamide, and involved-field radiotherapy. A durable complete remission was achieved and lasted for 4 years. When the disease recurred in 1995, she was found to have an autoimmune syndrome in addition to pleural effusion, a posterior mediastinal mass and a left adrenal mass. The autoimmune manifestations were seen as sclerodenna, high titers of rheumatoid factor and anti-nuclear antibody. We adopted a novel HDFL regimen, which is composed of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin, for this patient. Complete remission was achieved again, and autoimmune syndrome was well controlled.[SDGs]SDG3antinuclear antibody; cisplatin; cyclophosphamide; doxorubicin; fluorouracil; folinic acid; rheumatoid factor; adrenal tumor; adult; article; autoimmunity; cancer recurrence; cancer regression; case report; complication; drug therapy; female; human; human tissue; intravenous drug administration; mediastinum mass; oral drug administration; pleura effusion; priority journal; scleroderma; thymus cancer; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Thymus Neoplasmsjournal article91374932-s2.0-0030937624